Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (131)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (4)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (448)
  2. Department of Medicine (448)
  3. Hematologic Malignancies, Division of (448)
  4. Lymphoma (448)
  5. Hematology-Oncology Fellows (228)
  6. Survivorship Research (209)

More Groups

People
  1. Andrew Zelenetz (143)
  2. Ariela Noy (132)
  3. Paul Hamlin (126)
  4. Gilles Salles (114)
  5. Steven Horwitz (112)
  6. Gunjan Shah (111)

More People

Years
  1. 2025 (19)
  2. 2024 (58)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (187)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. Blood Cancer Journal (15)
  6. British Journal of Haematology (14)

More Publications

Publishers
  1. American Society of Hematology (207)
  2. Elsevier Inc. (45)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (33)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and clinical activity of atezolizumab (anti-PDL1) in combination with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma
    Meeting Abstract

    Till, B. G.; Park, S. I.; Popplewell, L. L.; Goy, A.; Penuel, E.; Venstrom, J. M.; Liu, B.; Fingerle-Rowson, G.; Byon, J.; Woodard, P.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma
    Meeting Abstract

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • The clonal architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia shows highly variable subclonal distribution, and multiple mutations within individual patients indicative of targeted genomic instability
    Meeting Abstract

    Xu, L.; Hunter, Z.; Tsakmaklis, N.; Cao, Y.; Yang, G.; Chen, J.; Liu, X.; Kanan, S.; Castillo, J. J.; Tai, Y. T.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Preliminary results from a phase 1/2, open-label, dose-escalation clinical trial of IMO-8400 in patients with relapsed or refractory Waldenstrom's macroglobulinemia
    Meeting Abstract

    Thomas, S. K.; Harb, W. A.; Beck, J. T.; Nashat, G.; Palomba, M. L.; Ansell, S. M.; Eradat, H.; Libby, E. N.; Advani, R. H.; Hajdenberg, J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: Results from a multicenter, phase 2 study
    Meeting Abstract

    Fowler, N.; Nastoupil, L.; de Vos, S.; Knapp, M.; Flinn, I. W.; Chen, R.; Advani, R. H.; Bhatia, S.; Martin, P.; Mena, R.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • High-depth, targeted, next generation sequencing identifies novel genetic alterations in cutaneous T-cell lymphoma
    Meeting Abstract

    Argyropoulos, K. V.; Horwitz, S. M.; Rapaport, F.; Velardi, E.; Myskowski, P.; Querfeld, C.; Pulitzer, M.; Dogan, A.; Gallagher, M.; Socci, N. D.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Ibrutinib in previously treated patients with Waldenström's macroglobulinemia is highly active, produces durable responses, and is impacted by MYD88 and CXCR4 mutation status
    Meeting Abstract

    Treon, S.; Tripsas, C.; Meid, K.; Warren, D.; Varma, G.; Green, R.; Argyropoulos, K.; Yang, G.; Cao, Y.; Xu, L.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial
    Meeting Abstract

    Owens, C. N.; Iannotta, A.; Gerecitano, J. F.; Matasar, M. J.; Noy, A.; Moskowitz, C. H.; Drullinsky, P.; Palomba, M. L.; Straus, D. J.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma
    Meeting Abstract

    Mehta-Shah, N; Lunning, M. A.; Boruchov, A. M.; Ruan, J.; Nair, S.; Lynch, P.; Byrne, R.; Moskowitz, A. J.; Matasar, M. J.; Gerecitano, J. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save